IMDX
Insight MolecularยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
IMDX Profile
Insight Molecular Diagnostics Inc.
A company focused on the field of molecular diagnostics,developing precision medicine technologies primarily in the field of cancer care
2 International Plaza Dr., Suite 510, Nashville, Tennessee 37217
--
Insight Molecular Diagnostics Inc., incorporated in California in 2009, is a majority-owned subsidiary of Bio Time. The Company is a precision diagnostic company focused on developing and commercializing proprietary tests in three areas: VitaGraft, a blood-based solid organ transplant monitoring test, DetermaIO, a gene expression test that evaluates tumor microenvironments to predict responses to immunotherapy, and DetermaCNI, a blood-based monitoring tool to monitor treatment outcomes in cancer patients. The company is continuing to develop DetermaIO, a test with promising data supporting its potential to help identify patients who may respond to checkpoint inhibitor drugs. These new drugs modulate the immune response and show activity in a variety of solid tumor types including non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).
